NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of CreXus Investment Corp. (“CreXus” or the “Company”) (NYSE: CXS) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Annaly Capital Management, Inc. (NYSE: NLY) in an all-cash deal valued at approximately $839 million. Under the terms of the proposed transaction, CreXus stockholders will receive $12.50 in cash for each share of CreXus common stock they own.
Request more information now by clicking here: www.faruqilaw.com/CXS. There is no cost or obligation to you.
Whether CreXus’ Board of Directors is acting in accordance with their fiduciary duties to CreXus’ stockholders to conduct an adequate and fair sales process to sell the Company, whether the proposed transaction undervalues CreXus’ shares, whether CreXus’ Board of Directors is adequately negotiating a price increase for the proposed transaction and by how much this proposed transaction undervalues the Company to the detriment of CreXus’ shareholders is the key focus of this investigation.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.
If you own common stock in CreXus and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/CXS or contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330.
Attorney Advertising. (C) 2012 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.